Akademik Veri Yönetim Sistemi
5th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2022) , 23 - 25 Kasım 2022, ss.1322-1327
Glioblastoma (GB) (stage IV) is the most common and aggressive primary brain tumor in adults and, even
with the standard treatment with the chemotherapy drug Temozolomide (TMZ), the median survival of patients
is still limited to only 12.6 months. Therefore, natural compounds such as flavonoids that can be used to treat
GB can improve the success of TMZ treatment. Our aim is to examine the effects of fisetin, which is widely
used in various cancers, on the treatment of GB cells as combined with TMZ. In the present study, cell viability
of TMZ and fisetin in T98G cells was determined by real-time measurements via high-tech xCELLigence
analysis. In addition, to evaluate the effects of fisetin alone and in combination with TMZ on GB cell
aggressiveness; its invasive feature with wound healing test and its effects on adhesion-independent cell
proliferation with colony formation test were performed. Fisetin alone reduced the cell proliferation and the
IC50 value of fisetin was 16,40 µmol/L at 24h. Fisetin alone and combined with TMZ suppressed invasive
ability in the T98G cell line. At the end of 24h of wound scratches, the percentages of wound widths were
plotted in TMZ, Fisetin, and TMZ+Fisetin groups as 75.56% (p<0,0001), 90.13% (p<0,0001), 98.03%
(p<0,0001), respectively while the wound width of the control group was only 13.95%. Moreover, the colony
formation and the number of colonies were inhibited more than a hundred times with the TMZ+Fisetin
combination treatment compared to untreated cells (p<0,0001). Our study highlights that fisetin and
combination therapy can reduce tumor aggressiveness by inhibiting the invasion and colony ability of GB.
Overall, it has been predicted that fisetin may be a new drug candidate by improving the life quality of patients
and increasing the effectiveness of TMZ in the GB treatment with further studies.
Keywords: Glioblastoma, Therapy, Temozolomide, Fisetin, Tumor aggressiveness